Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 3Gastrointestinal 3Tumor-Agnostic 1Thoracic 1Head & Neck 1Gynecologic 1Breast 1

Conditions

Breast Neoplasms 1

Interventions

Paclitaxel 162Fulvestrant 155Trastuzumab 154pembrolizumab 144Letrozole 136Carboplatin 118pertuzumab 104Cyclophosphamide 102Capecitabine 101Specimen Handling 100Anastrozole 90palbociclib 85abemaciclib 81Magnetic Resonance Spectroscopy 81exemestane 76Tamoxifen 75Docetaxel 75ribociclib 74trastuzumab deruxtecan 69Radiotherapy 62Biopsy 60Surveys and Questionnaires 56Gemcitabine 52130-nm albumin-bound paclitaxel 52sacituzumab govitecan 50olaparib 50Standard of Care 50Blood Specimen Collection 50Taxes 47Doxorubicin 46

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Artificial Intelligence × Breast × 1 year × Clear all
NCT04340180 2026-01-22

Evaluating the Performance of AI in Evaluating Breast MRI Performed With Dose Reduction

University of Alabama at Birmingham

Phase 1 Completed
20 enrolled
Breast

Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡